Drug Trial Radar · NCT05528510
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
418
Actual
Start
Sep 13, 2022
Primary completion
Apr 2, 2024
Study completion Oct 6, 2028
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Sep 6, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in participants with moderately to severely active ulcerative colitis (UC).
Conditions
- Colitis, Ulcerative
Interventions
Guselkumab Dose 1Drug
Guselkumab (Dose 1) will be administered as SC injection.
Guselkumab Dose 2Drug
Guselkumab (Dose 2) will be administered as SC injection.
Guselkumab Dose 3Drug
Guselkumab (Dose 3) will be administered as SC injection.
PlaceboOther
Placebo will be administered as SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants in Clinical Remission at Week 12Time frame: Week 12
Locations
236 sites in 25 countries. Site status is shown where the registry gives one.
Research Solutions of Arizona
Litchfield Park, Arizona
Om Research LLC 1
Apple Valley, California
Om Research LLC
Lancaster, California
Medical Associates Research Group, Inc.
San Diego, California
Peak Gastroenterology Associates
Colorado Springs, Colorado
Gastro Florida
Clearwater, Florida
I.H.S. Health. LLC
Kissimmee, Florida
Columbus Clinical Services LLC
Miami, Florida
Vista Health Research, LLC
Miami, Florida
Orlando Health
Orlando, Florida
Theia Clincial Research, LLC
Temple Terrace, Florida
Digestive Healthcare of Georgia, P.C
Atlanta, Georgia
Atlanta Gastroenterology Associates
Atlanta, Georgia
Gastroenterology Associates of Central GA
Macon, Georgia
Cotton O'Neil Digestive Health Center
Topeka, Kansas
Clinical Research Institute of Michigan, LLC
Chesterfield, Michigan
Detroit Clinical Research Center
Farmington Hills, Michigan
Smart Medical Research
Hollis, New York
University of North Carolina
Chapel Hill, North Carolina
Peters Medical Research
High Point, North Carolina
Dayton Gastroenterology, Inc
Dayton, Ohio
Gastro Intestinal Research Institute of Northern Ohio LLC
Westlake, Ohio
Allegheny General Hospital of Research
Pittsburgh, Pennsylvania
Frontier Clinical Research
Uniontown, Pennsylvania
Gastroenterology Associates of Orangeburg, SC
Orangeburg, South Carolina
Southern Star Research Institute, LLC
San Antonio, Texas
UT Health Science Center at San Antonio
San Antonio, Texas
Tyler Research Institute, LLC
Tyler, Texas
Victoria Gastroenterology
Victoria, Texas
Care Access Research, Ogden
Ogden, Utah
Gastroenterology Associates
Salt Lake City, Utah
Gastroenterology Associates of Tidewater
Chesapeake, Virginia
Cer Instituto Medico
Buenos Aires, Argentina
Hospital General de Agudos José Maria Ramos Mejía
Buenos Aires, Argentina
Clinica Adventista Belgrano
Ciudad de Buenos Aires, Argentina
Sanatorio Duarte Quiroz
Córdoba, Argentina
Hospital Privado Universitario De Cordoba
Córdoba, Argentina
Hospital Italiano de La Plata
La Plata, Argentina
Centro de Investigaciones Medicas Mar Del Plata
Mar del Plata, Argentina
Hospital Provincial del Centenario
Rosario, Argentina
Showing 40 of 236 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.